Expand ATXS Menu
ATXS MENU

ATXS Latest Press Releases

-- January 23, 2025 --

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis Business Wire 8:00 AM

-- January 13, 2025 --

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE Business Wire 8:00 AM

-- January 3, 2025 --

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:10 PM

-- December 11, 2024 --

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE Business Wire 8:00 AM

-- December 3, 2024 --

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:10 PM

-- November 13, 2024 --

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update Business Wire 4:10 PM
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference Business Wire 8:00 AM

-- November 4, 2024 --

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:10 PM

-- October 30, 2024 --

Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting Business Wire 8:00 AM

-- October 21, 2024 --

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting Business Wire 8:00 AM

-- October 16, 2024 --

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics' Investigational Therapy for the Treatment of Hereditary Angioedema Business Wire 8:00 AM

-- October 2, 2024 --

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:10 PM

-- September 30, 2024 --

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema Business Wire 8:00 AM

-- September 27, 2024 --

Astria Therapeutics to Present at Upcoming Global Angioedema Forum Business Wire 8:00 AM

-- September 19, 2024 --

Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress Business Wire 8:00 AM

-- September 4, 2024 --

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:10 PM

-- August 30, 2024 --

Astria Therapeutics to Present at Upcoming Bradykinin Symposium Business Wire 8:00 AM

-- August 29, 2024 --

Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference Business Wire 8:00 AM